Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 442-449

  Potkin, Steven G ^a   Phiri, Phillip ^b   Szegedi, Armin ^b   Zhao, Jun ^b   Alphs, Larry ^c,d   Cazorla, Pilar ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e JOHNSON AND JOHNSON   (United States)

Author keywords

Asenapine; Negative symptoms; Olanzapine; Schizophrenia; Treatment response

Indexed keywords

ASENAPINE; OLANZAPINE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYMPTOM ASSESSMENT SCALE 16; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ASENAPINE; NEGATIVE SYMPTOMS; OLANZAPINE; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886251333     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.024     Document Type: Article

References (26)

1. Abbas A.I., Hedlund P.B., Huang X.P., Tran T.B., Meltzer H.Y., Roth B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009, 205(1):119-128.
2. Alphs L., Morlock R., Coon C., van Willigenburg A., Panagides J. The 4-Item Negative Symptom Assessment (NSA-4) instrument: a simple tool for evaluating negative symptoms in schizophrenia following Brief training. Psychiatry (Edgmont). 2010, 7(7):26-32.
3. Alphs L.D., Summerfelt A., Lann H., Muller R.J. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol. Bull. 1989, 25(2):159-163.
4. Axelrod B.N., Goldman R.S., Alphs L.D. Validation of the 16-item Negative Symptom Assessment. J. Psychiatr. Res. 1993, 27(3):253-258.
5. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33(4):1013-1022.
6. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 1998, 155(6):751-760.
7. Buchanan R.W., Ball M.P., Weiner E., Kirkpatrick B., Gold J.M., McMahon R.P., Carpenter W.T. Olanzapine treatment of residual positive and negative symptoms. Am. J. Psychiatry 2005, 162(1):124-129.
8. Buchanan R.W., Panagides J., Zhao J., Phiri P., den H.W., Ha X., Kouassi A., Alphs L., Schooler N., Szegedi A., Cazorla P. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J. Clin. Psychopharmacol. 2012, 32(1):36-45.
9. Daniel D.G., Alphs L., Cazorla P., Bartko J.J., Panagides J. Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. Clin. Schizophr. Relat. Psychos. 2011, 5(2):87-94.
10. Fleming K., Potkin S.G., Binneman B., Keller D., Alphs L. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. ENP 2007, 17(4):S466. (abstract).
11. Ho B.C., Nopoulos P., Flaum M., Arndt S., Andreasen N.C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry 1998, 155(9):1196-1201.
12. Laughren T., Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006, 32(2):220-222.
13. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37(2):255-256.
14. Lieberman J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J. Clin. Psychiatry 2007, 68(2):e04.
15. Makinen J., Miettunen J., Jaaskelainen E., Veijola J., Isohanni M., Koponen H. Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Res. 2010, 178(1):121-125.
16. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
17. Möller H.J. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003, 17(11):793-823.
18. Norman R.M., Malla A.K., McLean T., Voruganti L.P., Cortese L., McIntosh E., Cheng S., Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000, 102(4):303-309.
19. Potkin S.G., Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 2007, 68(10):1492-1500.
20. Provencher H.L., Mueser K.T. Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia. Schizophr. Res. 1997, 26(1):71-80.
21. Saphris (asenapine sublingual tablets) [prescribing information] 2013, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ.
22. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 2009, 23(1):65-73.
23. Siddiqui O., Hung H.M., O'Neill R. MMRM vs. LOCF: a compresensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 2009, 19(2):227-246.
24. Siegel S.J., Irani F., Brensinger C.M., Kohler C.G., Bilker W.B., Ragland J.D., Kanes S.J., Gur R.C., Gur R.E. Prognostic variables at intake and long-term level of function in schizophrenia. Am. J. Psychiatry 2006, 163(3):433-441.
25. Stahl S.M., Malla A., Newcomer J.W., Potkin S.G., Weiden P.J., Harvey P.D., Loebel A., Watsky E., Siu C.O., Romano S. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J. Clin. Psychopharmacol. 2010, 30(4):425-430.
26. Velligan D.I., Alphs L., Lancaster S., Morlock R., Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009, 169(2):97-100.